how do i drink the glp 1 GLP-1 Support Mix · Mixed Berry – StayWell Langers wades into functional waters

Batsis is particularly concerned about the risks of sarcopenia, which can be a problem for people with excess fat as well as those who are thin and may appear frailer

Husain, M

Similarly, the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) [47] and the Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) [48] trials expanded inclusion beyond diabetes mellitus, showing that dapagliflozin and empagliflozin significantly reduced the risk of kidney outcomes, with consistent benefits across a wide range of eGFR and albuminuria

This distinguishes it from dual agonists such as tirzepatide and single agonists such as semaglutide, though no head-to-head comparative trials have been conducted and no superiority claims can be made at this stage

2025 Aug;7(8):1536-1549

Diabetes Care 40 , 10731081 (2017)